Bispecific Antibodies Market to Grow with a CAGR of 9.43% through 2028

Increasing applications in diverse therapeutic areas and a strong focus on research and development are expected to drive the Global Bispecific Antibodies Market growth in the forecast period, 2024-2028.

 

According to TechSci Research report, “Bispecific Antibodies Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Bispecific Antibodies Market stood at USD 5.67 billion in 2022 and is anticipated to grow with a CAGR of 9.43% in the forecast period, 2024-2028. This can be attributed to the rising prevalence of cancer. The prevalence of cancer continues to rise globally, making it one of the leading causes of mortality. Bispecific antibodies have gained substantial traction in the field of oncology due to their unique ability to simultaneously target cancer cells and engage the body's immune system. This dual targeting approach holds the promise of improving treatment outcomes and reducing side effects, driving the demand for bispecific antibodies in cancer therapy.

Furthermore, a growing emphasis on patient-centered care is shaping the bispecific antibodies market. Healthcare providers are increasingly considering patient preferences, treatment tolerability, and quality of life when selecting therapies. This trend drives the development of therapies with improved safety and convenience profiles.

The surging incidence of cancers such as breast cancer, lung cancer, prostate cancer, and other chronic ailments stands out as a primary catalyst for market expansion. These molecules offer a precise approach to combat specific cancer types by concurrently targeting cancer cells and the immune system. Moreover, the growing demand for personalized medicine and the shift toward targeted therapies have contributed to the market's upward trajectory.

           

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Bispecific Antibodies Market.”

 

Furthermore, strategic collaborations and partnerships between pharmaceutical companies and biotechnology firms have played a pivotal role in advancing the research and development of bispecific antibodies. These partnerships have expedited the discovery and clinical advancement of innovative bispecific antibodies, further fueling market growth. For example, in January 2022, Amgen and Generate Biomedicines joined forces in a research partnership to explore and develop protein therapies for five distinct clinical targets spanning various therapeutic domains. Additionally, in May 2023, the U.S. FDA granted approval to EPKINLY (epcoritamab-bysp), marking the first-ever authorized bispecific antibody for the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) in adult patients.

The COVID-19 pandemic has presented a dual impact on the bispecific antibodies industry. On one hand, it has underscored the crucial role of bispecific antibodies in addressing infectious diseases. However, the pandemic has also introduced challenges in the form of disruptions in the supply chain, resulting in delays in bispecific antibody research and development. Furthermore, economic uncertainties and budget constraints have affected research institutions and biotech companies, potentially influencing their prioritization and allocation of resources for bispecific antibody development.

Furthermore, various advancements undertaken by industry participants and the growing collaborations between industry and academia have significantly propelled the global market. For instance, in March 2023, Thermo Fisher Scientific Inc. collaborated with Arsenal Bioscience, a cell therapy company, to facilitate and support the clinical manufacturing of Autologous T-Cell Therapies.

The Global Bispecific Antibodies Market is segmented into indication, regional distribution, and company.

Based on its indication, Cancer is poised to dominate the Global Bispecific Antibodies Market for several compelling reasons. First and foremost, cancer remains one of the most prevalent and challenging diseases worldwide, driving continuous demand for innovative and effective treatments. Bispecific antibodies, with their unique ability to simultaneously target multiple cancer-specific antigens, offer a promising avenue for improved therapeutic outcomes. Additionally, ongoing advancements in biotechnology and immunotherapy research have led to the development of increasingly sophisticated bispecific antibody candidates, which are gaining traction in clinical trials. Furthermore, the rising investment in oncology research and the expanding patient pool in emerging markets contribute to the growth potential of this market segment. With the pressing need for more efficacious cancer therapies, bispecific antibodies are well-positioned to play a pivotal role in shaping the future of cancer treatment, solidifying their dominance in the Global Bispecific Antibodies Market.

Based on region, North America is poised to dominate the Global Bispecific Antibodies Market in 2022 for several compelling reasons. Firstly, the region boasts a robust pharmaceutical and biotechnology industry with a strong focus on research and development, particularly in the field of immunotherapy and oncology. This commitment to innovation has led to the emergence of cutting-edge bispecific antibody therapies, which are gaining significant traction. Secondly, North America benefits from a well-established healthcare infrastructure and a vast patient population, particularly in the United States, where cancer rates are high. This combination of research prowess and a sizable addressable market creates a favorable environment for the adoption and commercial success of bispecific antibody treatments. Additionally, regulatory agencies such as the FDA have been receptive to novel therapeutic approaches, expediting the approval process for these groundbreaking drugs. Given these factors, North America is poised to maintain its dominance in the Global Bispecific Antibodies Market for the foreseeable future.

 

Major companies operating in Global Bispecific Antibodies Market are:

• Amgen Inc
• Roche Holding AG
• Genentech Inc
• Akeso Inc
• Janssen Pharmaceuticals Inc
• Taisho Pharmaceutical Co Ltd
• Immunocore Ltd

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.

 

“The global bispecific antibodies market is undergoing rapid transformation, driven by an array of emerging trends. These trends include diversification of therapeutic applications, novel antibody formats, T-cell engaging antibodies, combination therapies, personalized medicine, expanded clinical trials, strategic collaborations, regulatory advancements, and a patient-centric approach. As these trends converge, they promise to reshape the landscape of healthcare, offering more effective and precise treatment options for a wide range of diseases. It is an exciting time for the bispecific antibodies market, as it continues to evolve and push the boundaries of what is possible in modern medicine,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Bispecific Antibodies Market By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Bispecific Antibodies Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Bispecific Antibodies Market.

 

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com